2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Non-Biological Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1630 Efficacy and safety of venetoclax combined with homoharringtonine and low-dose cytarabine (VHA) in adult patients with newly diagnosed acute myeloid leukemia: A prospective trial

Yin Liu, Tanzhen Wang2, Xin Kong3, Zhang Jian4, Hai-xia Zhou, MD, PhD5, Suning Chen6, Ying Wang, MD, PhD7, Xiaowen Tang, MD8, Xu Yang, PhD9, Depei Wu Sr, MD10, Huiying Qiu, MD11
1 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
2 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
3 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
4 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
5 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
6 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
7 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
8 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
9 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
10 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
11 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

Background:
Venetoclax(VEN) combined with hypomethylating agents has been approved as frontline therapy for older patients or those ineligible for intensive chemotherapy with acute myeloid leukemia (AML). Multiple venetoclax-based induction regimens have been applied to fit patients with newly diagnosed AML to improve the outcomes, yet the optimal combination regimen remains undefined. Herein, we report the results of a prospective trial conducted to investigate the efficacy and safety of ven combined with homoharringtonine and low-dose cytarabine (VHA) as the induction regimen in untreated adult AML.

Methods:
Previously untreated adult patients (aged from 18 to 60 years old) with newly diagnosed AML who met the inclusion criteria and were eligible for intensive chemotherapy were enrolled in this prospective study. All patients received one induction cycle of the triple combination regimen. The primary endpoints were overall response rate (ORR) assessed on day 28 after treatment initiation. Secondary endpoints included the incidence of adverse events (AEs) and overall survival (OS). The follow-up period commenced upon enrollment of the first enrolled case, and concluded1 year after the last patient enrolled.

Results:
By the last follow-up of April 2026, a total of 63 newly diagnosed AML patients were treated with VHA regimen available for analysis, with a median age of 40 years old (range 18–59), including 29 males and 34 females. According to the 2022 European LeukemiaNet (ELN) prognostic stratification system for AML, 16 (25.4%) patients were classified as favorable-risk, 26 (41.3%)as intermediate-risk, and 21 (33.3%) as adverse-risk. The ORR on day 28 was 95.3% (60/63), and the composite complete response (CRc) rate was 88.8% (56/63). Among patients who achieved CRc, 94.6% (53/56) attained measurable residual disease (MRD) negativity. Compared with the historical IA-12 cohort (n=94) in our center, the VHA group demonstrated superior ORR (95.3% vs 89.4%), CRc (88.8% vs 79.0%) and MRD-negative rates among CRc patients (94.6% vs 76.0%). Notably, among intermediate-risk AML patients, the ORR and CRc were 92.4% (24/26) and 84.6% (22/26) , respectively. Meanwhile, among adverse-risk patients, the ORR and CRc were 95.3% (20/21) and 85.7% (18/21), respectively. All 5 patients with mononuclear cells expression responsed to therapy: 4 complete response (CR) and 1 achieved partial response (PR). Additionally, hematologic recovery occurred relatively rapidly. The median time to neutrophil recovery was 17 days (range 0-32). The median time to achieve a platelet count ≥20×109/L was 2 days (range 0-27), while the median time to attain sustained platelets ≥30×109/L independent of platelet transfusion was 8 days (range 0-35).

Grade 3-4 neutropenia and thrombocytopenia occurred in 98.4% and 100% of patients, respectively. The most common non-hematologic adverse events included febrile neutropenia (44.4%), nausea and vomiting (15.8%), pulmonary infection (7.9%), and bloodstream infection (6.3%). 2 patients developed persistent pulmonary infection after admission, and 1 patient suffered from perianal infection. Two patients with pulmonary infection and 1 patient with perianal infection had been infected before admission. One patient was transferred to the ICU due to severe infection, but finally recovered and achieved remission. No deaths occurred during the treatment period. Tumor lysis syndrome (TLS) was not observed, however, a few individuals occurred transient creatinine or liver enzymes elevation, which could be improved by adequate hydration and supportive treatment. The median duration of hospital stay was 27 days(range: 20-52). With a median follow-up of 532 (range 55-1095) days, the median OS was not reached. The 1-year and 2-year OS rates were 84.1% and 72.4%, respectively. 16 died due to disease refractory or relapse.

Conclusion:
Our study underlined the effective and safe induction regimen for adult patients with newly diagnosed AML, with favorable ORR and AEs rate, particularly to those with intermediate-risk and adverse-risk genetic features. This regimen is associated with accelerated hematologic recovery and reduced transfusion dependence, which potentially conferring to economic benefits in addition to its clinical advantages.

Yin Liu: No relevant conflicts of interest to declare.